18 Jan EG 427
Philippe Chambon, M.D., Ph.D., CEO
April 13 | 9:30am | Dark Horse Consulting Ballroom
EG 427 develops next-generation gene therapies specifically targeted to underlying mechanism of action, at the local level, in order to address major chronic diseases where it matters and in a safe and cost-effective manner. Non-replicative Herpes Simplex Virus 1 (nrHSV-1) derived vectors are a powerful tool to achieve highly selective, safe, and durable expression of transgenes addressing localized diseases in the peripheral nervous system and beyond.